Stepping up by stepping down

There are few diseases with treatment burdens as intense as cystic fibrosis. Patient survey data suggests that many people with CF (PwCF) prioritize a less burdensome treatment regimen over outcome measures such as lung function and even life expectancy [1]. These values-based trade-offs have long existed and are potentially accentuated in the era of elexacaftor-tezacaftor-ivacaftor (ETI) when many PwCF have experienced clinical improvements far exceeding that of time-consuming mucolytics and inhaled antibiotics.

Source: Journal of Cystic Fibrosis - December 21, 2023 Category: Respiratory Medicine Authors: Christine Bielick Kotkowski, A. Whitney Brown Source Type: research